公开(公告)号：US20220184305A1

公开(公告)日：2022-06-16

申请号：US17653107

申请日：2022-03-01

申请人： Beta Bionics, Inc.

发明人： Michael J. Rosinko ,  Himanshu Patel ,  Edward R. Damiano ,  Firas H. El-Khatib

IPC分类号： A61M5/172 ,  A61M5/142 ,  G16H20/17

摘要： Blood glucose control systems are disclosed. A blood glucose control system can receive a glucose level signal from a glucose sensor operatively coupled to a subject. The system can decode encoded data of the glucose level signal to obtain the glucose level of the subject and the indication of the glucose trend. The system can automatically calculate the dose control signal using a control algorithm configured to calculate regular correction boluses of glucose control agent in response to at least the glucose level of the subject. The system can select a dose control signal encoding profile from a plurality of dose control signal encoding profiles and, based on the dose control signal encoding profile, encode the dose control signal such that the pump controller can read the dose control signal. The system can transmit an encoded dose control signal to the pump controller.

公开(公告)号：US20220096748A1

公开(公告)日：2022-03-31

申请号：US17492007

申请日：2021-10-01

申请人： Beta Bionics, Inc.

发明人： Firas H. El-Khatib ,  Edward R. Damiano ,  Edward B. Raskin ,  David Chi-Wai Lim ,  Michael J. Rosinko ,  John R. Costik

IPC分类号： A61M5/172 ,  G16H20/17 ,  G16H40/40 ,  G06F8/656 ,  H04W76/10 ,  A61M5/142 ,  G06F8/61 ,  H04L29/08 ,  G16H40/60 ,  G16H80/00 ,  A61M5/168 ,  G08B21/04 ,  G08B21/18 ,  G16H40/67 ,  G06F21/30 ,  G06F21/31 ,  G06F21/62 ,  G06F21/84 ,  G16H10/60 ,  G16H50/30 ,  G06F3/0488 ,  G06F8/65 ,  H04L29/06 ,  H04W76/14 ,  H04L9/08 ,  H04L9/30 ,  G06F3/0484

摘要： An automated blood glucose control system can provide automatic delivery of glucose control therapy to a subject and receive information about manual glucose control therapy provided to the subject. The automated blood glucose control system can indicate an amount of a bolus of medicament via a control algorithm configured to control blood glucose level in the subject. The automated blood glucose control system can indicate an amount of a manual bolus of medicament, which can be used to model a diminishment of the medicament in the subject over time based at least in part on the manual bolus of medicament.

公开(公告)号：US20220072227A1

公开(公告)日：2022-03-10

申请号：US17478071

申请日：2021-09-17

申请人： Beta Bionics, Inc.

发明人： Himanshu Patel ,  Michael J. Rosinko ,  Edward R. Damiano ,  David Chi-Wai Lim ,  Firas H. El-Khatib ,  John R. Costik ,  Justin P. Brown ,  Bryan Dale Knodel

IPC分类号： A61M5/172 ,  G16H20/17 ,  G16H40/40 ,  G06F8/656 ,  H04W76/10 ,  A61M5/142 ,  G06F8/61 ,  H04L29/08 ,  G16H40/60 ,  G16H80/00 ,  A61M5/168 ,  G08B21/04 ,  G08B21/18 ,  G16H40/67 ,  G06F21/30 ,  G06F21/31 ,  G06F21/62 ,  G06F21/84 ,  G16H10/60 ,  G16H50/30 ,  G06F3/0488 ,  G06F8/65 ,  H04L29/06 ,  H04W76/14 ,  H04L9/08 ,  H04L9/30 ,  G06F3/0484

摘要： Systems and methods are disclosed herein for switching an application executing on an ambulatory medical device to a new application without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device may receive an indication that an update to an application executing on the ambulatory insulin pump is available, establish a communication connection to a host computing system, download and install the application update, while a prior version of the application continues to run. The disclosed systems and methods can confirm successful installation of the application update on the ambulatory medical device and switch control of the ambulatory medical device from the prior version to the new version of the application without interrupting therapy provided to the subject.

公开(公告)号：US11154656B2

公开(公告)日：2021-10-26

申请号：US17062436

申请日：2020-10-02

申请人： Beta Bionics, Inc.

发明人： Firas H. El-Khatib ,  Edward R. Damiano ,  Edward B. Raskin ,  David Chi-Wai Lim ,  Michael J. Rosinko ,  John R. Costik

IPC分类号： A61M5/172 ,  A61M5/142 ,  G16H20/17 ,  G16H40/40 ,  G06F8/656 ,  H04W76/10 ,  G06F8/61 ,  H04L29/08 ,  G16H40/60 ,  G16H80/00 ,  A61M5/168 ,  G08B21/04 ,  G08B21/18 ,  G16H40/67 ,  G06F21/30 ,  G06F21/31 ,  G06F21/62 ,  G06F21/84 ,  G16H10/60 ,  G16H50/30 ,  G06F3/0488 ,  G06F8/65 ,  H04L29/06 ,  H04W76/14 ,  H04L9/08 ,  H04L9/30 ,  G06F3/0484 ,  G08B25/00 ,  A61B5/145 ,  G16H40/00

摘要： An automated blood glucose control system can provide automatic delivery of glucose control therapy to a subject and receive information about manual glucose control therapy provided to the subject. The automated blood glucose control system can indicate an amount of a bolus of medicament via a control algorithm configured to control blood glucose level in the subject. The automated blood glucose control system can indicate an amount of a manual bolus of medicament, which can be used to model a diminishment of the medicament in the subject over time based at least in part on the manual bolus of medicament.

公开(公告)号：US20210106750A1

公开(公告)日：2021-04-15

申请号：US17110497

申请日：2020-12-03

申请人： Trustees of Boston University ,  Beta Bionics, Inc.

发明人： Edward R. Damiano ,  Rajendranath Selagamsetty ,  Firas H. El-Khatib ,  Bryan D. Knodel ,  Raymond A. Carr

IPC分类号： A61M5/14 ,  A61J1/20 ,  A61M5/168

摘要： Multi-medicament infusion systems prevent cross-channeling of medicaments. A system may include one or more of an infusion pump, medicament reservoirs, a multi-channel fluid conduit, and an infusion set. Medicament reservoirs and/or collars may be sized and shaped differently such that the medicament reservoirs can only be inserted into the system under selected configurations.

公开(公告)号：US20210090726A1

公开(公告)日：2021-03-25

申请号：US17062356

申请日：2020-10-02

申请人： Beta Bionics, Inc.

发明人： Michael J. Rosinko ,  Edward R. Damiano ,  David Chi-Wai Lim ,  Firas H. El-Khatib ,  Himanshu Patel ,  John R. Costik ,  Justin P. Brown ,  Bryan Dale Knodel

IPC分类号： G16H40/40 ,  G16H20/17 ,  G16H40/67 ,  A61M5/142

摘要： Systems and methods are disclosed herein for updating an application controlling an ambulatory medical device such that application updates can be identified, downloaded and installed without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device may receive an indication that an update to an application executing on the ambulatory insulin pump is available, establish a communication connection to a host computing system configured to host the application update, and download the application update. The disclosed systems and methods can determine an execution time of an installation and install the downloaded application update without interrupting therapy provided by the ambulatory medical device to the subject.

公开(公告)号：US20210090706A1

公开(公告)日：2021-03-25

申请号：US17062353

申请日：2020-10-02

申请人： Beta Bionics, Inc.

发明人： Michael J. Rosinko ,  Edward R. Damiano ,  David Chi-Wai Lim ,  Firas H. El-Khatib ,  Justin P. Brown ,  Bryan Dale Knodel

IPC分类号： G16H20/17 ,  G08B21/18 ,  G06F3/0488 ,  G16H40/67 ,  G16H10/60 ,  G16H40/40 ,  G16H50/30 ,  H04L29/06 ,  G06F8/65 ,  A61M5/142 ,  A61M5/172

摘要： Systems and methods are disclosed herein for monitoring the status of an ambulatory medical device and the health condition of a subject that receives therapy from the ambulatory medical device. The ambulatory medical device can have a touchscreen display user interface to receive input signals from a user and display alarm conditions associated with the status of an ambulatory medical device or health condition of a subject. The disclosed methods and systems can determine whether status information received from a monitoring system interface satisfies an alarm condition for the ambulatory medicament device or for the subject. If the status information satisfies an alarm condition, the touchscreen user interface can display one or more alarm status indicators corresponding to the alarm condition. The user can activate a therapy change interface on the touchscreen display and modify a control parameter of the ambulatory medical device that controls the therapy delivery to the subject.

公开(公告)号：US20210085869A1

公开(公告)日：2021-03-25

申请号：US17062436

申请日：2020-10-02

申请人： Beta Bionics, Inc.

发明人： Firas H. El-Khatib ,  Edward R. Damiano ,  Edward B. Raskin ,  David Chi-Wai Lim ,  Michael J. Rosinko ,  John R. Costik

IPC分类号： A61M5/172 ,  A61M5/142

摘要： An automated blood glucose control system can provide automatic delivery of glucose control therapy to a subject and receive information about manual glucose control therapy provided to the subject. The automated blood glucose control system can indicate an amount of a bolus of medicament via a control algorithm configured to control blood glucose level in the subject. The automated blood glucose control system can indicate an amount of a manual bolus of medicament, which can be used to model a diminishment of the medicament in the subject over time based at least in part on the manual bolus of medicament.

公开(公告)号：US20210085868A1

公开(公告)日：2021-03-25

申请号：US17062426

申请日：2020-10-02

申请人： Beta Bionics, Inc.

发明人： David Chi-Wai Lim ,  Edward B. Raskin ,  Michael J. Rosinko ,  Edward R. Damiano ,  Firas H. El-Khatib ,  Himanshu Patel

IPC分类号： A61M5/172 ,  A61M5/142

摘要： An ambulatory medicament device can automatically resume medicament delivery after medicament delivery to a subject is suspended. Suspension of medicament delivery can occur for a temporary suspension period associated with a length of time that the delivery of the medicament is to be suspended. Resuming medicament delivery can occur upon determining that a resumption condition has occurred during the temporary suspension period.

公开(公告)号：US20210016005A1

公开(公告)日：2021-01-21

申请号：US17061990

申请日：2020-10-02

申请人： BETA BIONICS, INC.

发明人： Edward B. Raskin ,  David Chi-Wai Lim ,  Michael J. Rosinko ,  Firas H. El-Khatib ,  Edward R. Damiano

IPC分类号： A61M5/172 ,  G16H20/17 ,  G16H10/40 ,  G16H40/67

摘要： An automated blood glucose control system is configured to generate a backup therapy protocol comprising insulin therapy instructions derived from autonomously determined doses of insulin. The system generates a dose control signal using a control algorithm configured to autonomously determine doses of insulin to be infused into a subject for the purpose of controlling blood glucose of the subject based at least in part on a glucose level signal received from a glucose sensor. The system can track insulin therapy administered to the subject over a tracking period, including storing an indication of the autonomously determined doses of insulin delivered to the subject as basal insulin, as correction boluses of insulin, or as mealtime boluses of insulin. The system can generate a backup injection therapy protocol or a backup pump therapy protocol with insulin therapy instructions based at least in part on the insulin therapy administered to the subject over the tracking period.